01:14 AM EDT, 07/30/2026 (MT Newswires) -- Idorsia (IDIA.SW) said Thursday that it swung to a net loss in the first half, while revenue declined year over year. Net loss for the six months ended June 30 was 153 million francs, compared with a profit of 52 million francs a year earlier. Loss per share was 0.60 franc, compared with an EPS of 0.26 franc. The Swiss biopharmaceutical group's net revenue was 110 million francs, compared with 131 million francs a year ago. Further, the company maintained its 2026 guidance. It still expects Quviviq product sales of 200 million francs and an operating loss of 160 million francs for the year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.